Searched for
DEURUXOLITINIB
Sun Pharma shares in focus following US launch of LEQSELVITM, settlement with Incyte CorporationSun Pharma shares: In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Inc...15 Jul, 2025, 09.06 AM IST- US court lifts restrictions on Sun Pharma launching autoimmune disorder drugSun Pharmaceutical Industries Ltd announced that a US court has ruled in its favour, immediately vacating a preliminary injunction that res...10 Apr, 2025, 12.17 PM IST
- Sun Pharma's hair loss drug in the cross hairs in USLeqselvi is used for the treatment of alopecia areata, an autoimmune disease that leads to hair loss, and was approved by the US Food and D...03 Aug, 2024, 12.25 AM IST
- Sun Pharma gets US FDA nod for its specialty drug against baldnessSun Pharma announced FDA approval of Leqselvi (deuruxolitinib) 8 mg tablets for severe alopecia areata, marking a major milestone after acq...26 Jul, 2024, 11.57 AM IST
- Sun Pharma's drug to treat alopecia areata gets USFDA nodSun Pharmaceutical Industries Ltd announced that the USFDA has approved its drug LEQSELVI (deuruxolitinib) for treating adults with severe ...26 Jul, 2024, 11.09 AM IST
- Sun Pharma shares tumble 5% but brokerages raise target up to Rs 1,785. Should you buy, sell or hold?In Thursday's trading session on the BSE, shares of Sun Pharmaceutical Industries declined by 5%, reaching the day's low of Rs 1,467. This ...23 May, 2024, 10.54 AM IST
- Sun Pharma subsidiary partners with Aclaris Therapeutics for licensing agreementAs per the pact, Aclaris grants Sun Pharma exclusive rights to specific patents for using deuruxolitinib, Sun Pharma's JAK inhibitor, or ot...06 Dec, 2023, 07.51 AM IST
- Sun Pharma Q2 Results: Cons profit rises 6% YoY to Rs 2,385 crore, beats estimatesOperating profit, calculated as earnings before interest, taxes, depreciation, and amortization (EBITDA), for the quarter, rose nearly 8% o...01 Nov, 2023, 07.25 PM IST
- Sun Pharma files new drug application with USFDA for investigational medicine to treat alopeciaThe new drug application filing for deuruxolitinib with the USFDA is based on two pivotal Phase III trials, which included over 1,200 patie...06 Oct, 2023, 12.33 PM IST
- 'Sun Pharma eyes deals to push specialty play, EM business'Sun Pharma, India's largest drugmaker, is looking at acquisitions to boost its specialty pipeline and strengthen emerging markets business....30 May, 2023, 11.41 PM IST
- Sun facing some clouds is still a buy for analystsShares declined nearly 2.5% in Monday's trading before recouping most of its losses. The stock eventually closed at ₹968.50, down 0.14% fro...30 May, 2023, 06.40 AM IST
- Sun Pharma Q4 Results: Firm clocks cons PAT of Rs 1,984 crore, declares Rs 4/share dividendThe company approved a final dividend of Rs 4 per equity share which will be subject to the approval of the shareholders. The total dividen...27 May, 2023, 06.14 PM IST
- US FDA halts Sun Pharma's trials on dermatological drugThe FDA has also said that patients with alopecia areata - an autoimmune condition that results in patchy hair loss - on the 12 mg dose of ...02 May, 2023, 10.29 AM IST
- Sun Pharma completes acquisition of Concert PharmaceuticalsThe drug major has successfully completed the acquisition of Concert Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company ...06 Mar, 2023, 08.48 PM IST
- Sun Pharma to buy concert for $576 mConcert has pioneered the use of deuterium (a hydrogen isotope) in medicinal chemistry and has an extensive patent portfolio, including its...20 Jan, 2023, 12.32 AM IST
- Sun Pharma to acquire US-based Concert for $576 millionConcert's lead candidate, deuruxolitinib, is being evaluated as a treatment for autoimmune condition alopecia areata, which results in patc...19 Jan, 2023, 07.17 PM IST
- Sun Pharma to acquire US-based Concert for $576 millionConcert's lead candidate, deuruxolitinib, is being evaluated as a treatment for autoimmune condition alopecia areata, which results in patc...19 Jan, 2023, 07.04 PM IST
Load More
